Wolfe starts Stryker with an Outperform on leading orthopedics portfolio

As previously reported, Wolfe Research analyst Mike Polark initiated coverage of Stryker with an Outperform rating and $405 year-end 2025 price target. The firm sees Stryker as having “the number one orthopedics portfolio globally,” noting that the company is number two in knees, number two or three in hips, number one in trauma & extremities, and number one in orthopedic robots with Mako while its performance suggests clear evidence of consistent share capture across all categories the last 10 years. The company’s diversified portfolio means Stryker is “not only a leading brand in multiple physician specialties but also for hospital operators,” the analyst added.